Metformin treatment for 8 days impacts multiple intestinal parameters in high-fat high-sucrose fed mice

Amélie Bravard1,4, Céline Gérard1,4, Clémence Defois1, Bérengère Benoit1, Kassem Makki1,3, Emmanuelle Meugnier1, Dominique Rainteau2, Jennifer Rieusset1, Murielle Godet1 & Hubert Vidal1*

Although the mechanism of action of the antidiabetic drug metformin is still a matter of discussions, it is well accepted that the gut plays an important role. To gain more insights into the mechanisms occurring in the different regions of the intestine, adult male mice were fed a high-fat-high sucrose (HFS) diet for 8 days and treated with metformin by gavage (300 mg/day/kg body weight) during the HFS diet. Metformin counteracted HFS diet-induced overexpression of a network of genes involved in the transport of glucose and fatty acids in the different regions of the small intestine. It also induced beneficial modification of secondary bile acid profile in the caecum, with a reduction of deoxycholic acid and lithocholic acid levels and increased abundance of ursodeoxycholic acid and tauroursodeoxycholic acid, potentially leading to FRX inhibition. In parallel, metformin treatment was associated with specific changes of the microbiota composition in the lumen of the different regions of the intestine. Metformin induced a marked increase in the abundance of Akkermansia muciniphila in the lumen all along the gut and counteracted the effects of HFS diet on the abundances of some bacterial groups generally associated with metabolic disturbances (f-Lachnospiraceae, f-Petostreptococcaceae, g-Clostridium). Therefore, the present work clearly emphasises the role of all the regions of the intestinal tract in the beneficial action of the antidiabetic drug metformin in a prediabetic mouse model.

The oral antidiabetic drug metformin (1,1-dimethylbiguanide hydrochloride) is the first line therapy of type 2 diabetes mellitus (T2DM). Despite its use for more than 60 years, the mechanisms contributing to its effects on blood glucose levels are still subject of debates1,2. Clinical studies have demonstrated that metformin acts primarily by the reduction of exaggerated endogenous glucose production in diabetic patients, especially through a decrease of hepatic gluconeogenesis rate1. Animal studies and in vitro experiments in hepatocytes revealed an inhibition of complex I of the mitochondrial electron transfer chain and activation of AMP-activated protein kinase (AMPK), leading to the repression of gluconeogenic gene expression1,2. In parallel, several works have suggested that metformin may act primarily by targeting intestinal tract as it can accumulate and reach high concentrations in the small intestine1. Furthermore, oral administration of metformin appeared to reduce blood glucose more efficiently than the intravenous route3, and a gut-restricted formulation was shown to efficiently decrease glucose levels in T2DM patients4. It was also shown that metformin is able to inhibit intestinal glucose absorption in the proximal small intestine5, and to increase glucose uptake and utilization by the enterocytes6. Additional modifications of intestinal functions have been reported, including increased production of the incretin hormone glucagon-like peptide 1 (GLP1)7, stimulation of Goblet cells specialized in mucin production8 and bile acid pool modifications9. These effects can be related to a direct action of the drug on intestinal cells or to consequences of a modification of the gut microbiota. Indeed, it is currently well accepted that metformin is able to alter the overall structure and the functions of the gut microbiota10–12, and it was shown that metformin...
can stimulate directly the growth of specific bacterial species, notably *Akkermansia muciniphila*\textsuperscript{10,13,14}. However, the direct link between the modulation of microbiota and the metabolic actions of metformin is still debated\textsuperscript{16}. To gain more insights into the mechanisms that occur in the different regions of the intestinal tract in response to metformin treatment, we investigated in the present study the changes in a number of biological parameters in different regions of the intestinal tract after a short-term metformin treatment in high-fat high-sucrose (HFS) fed mice. In addition to its effects on the expression of key intestinal genes in different segments (duodenum, jejunum, ileum, colon), we evaluated the impact of the drug on the luminal microbiota composition of each gut segment, and we performed a bile acid profiling in the caecum of the animals. Mice were fed HFS diet for 8 days and were treated with metformin by daily gavage. We found multi-level effects of metformin, leading in one week to a restoration of most of the perturbations induced by HFS diet on gene expression, associated with modifications of the bile acid profile and of the luminal microbiota composition all along the gut.

**Results**

**Short metformin treatment prevented metabolic disturbances in HFS fed mice.** HFS feeding for a period of 8 days induced metabolic disturbances in adult C57BL/6J male mice, as evidenced by a significant rise in fasting glucose levels and a deterioration of glucose tolerance during ipGTT (Fig. 1). There was also an increase in body weight upon HFS feeding (mean gain of 1.7 ± 0.2 g in HFS vs 0.2 ± 0.1 in SD group). The admin-

![Figure 1](https://example.com/figure1.png)
administration of metformin was able to counteract these alterations, as reflected by the maintenance of normal body weight gain (mean gain of 0.1 ± 0.1 g) and the preservation of glucose tolerance, although the effect of metformin on fasting glucose levels did not reach statistical significance (Fig. 1).

Short metformin treatment restored the expression of important genes in intestinal regions. The different intestinal segments express specific patterns of genes allowing a spatial organization of a number of functions along the intestinal tract, such as nutrient digestion and absorption, chylomicron production, bile acid uptake, gut hormone secretion, or immune response and microbe defense. Therefore, we analyzed for each intestinal segment the expression of a specific set of genes after 8 days of HFS feeding with or without metformin. Regarding the genes coding for the apical sugar transporters (Fig. 2), namely the sodium-glucose cotransporter SGLT1 (encoded by Slc5a1) and the fructose transporter GLUT5 (Slc2a5), we found that HFS diet increased GLUT5 and SGLT1 expression in the duodenum, the main region of sugar absorption, while metformin counteracted these effects and significantly reduced GLUT5 expression in all segments of the intestine. We also observed that metformin was able to reduce Glut2 expression in the duodenum (data not shown).

Jejunum and ileum are the favored sites for lipid absorption. As shown in Fig. 3, HFS diet feeding significantly increased the gene expression of the main actors of apical fatty acid uptake (FAT/CD36 and FATP4), intracellular fatty acid transport (FA2PB2) and chylomicron synthesis (MTTP) in these two regions, while metformin restored their expression to basal levels (Fig. 3). In contrast, the ileal expressions of the apical sodium-dependent bile acid transporter (ASBT, coded by Slc10a2) and of the organic solute transporter-alpha (OSTα, coded by SLC51B, which exports bile acid across the enterocyte basolateral membrane), were not significantly affected by HFS diet or by metformin (Fig. 3). The mRNA level of the cholesterol transporter NPC1L1 was strongly decreased upon HFS diet in the jejunum and not modified by metformin treatment (Fig. 3).

Results regarding gut hormones and peptides are shown in Fig. 4. We analyzed the expression of the glucagon gene (Gcg), encoding GLP-1, in different regions of the gut. HFS diet was associated with an increase in Gcg expression in duodenum and jejunum and metformin treatment tended to restore its expression to basal level in duodenum and to slightly decrease it in the colon (Fig. 4). In the other regions, we did not find significant effect of metformin on Gcg gene expression. In contrast, the mRNA levels of gastric inhibitory polypeptide (GIP) and cholecystokinin (CCK) in duodenum, of neuropeptide Y (NPY) in jejunum, and of fibroblast growth factor 15 (FGF15) in ileum, which were all increased upon HFS feeding, were restored or down-regulated in the presence of metformin (Fig. 4). Finally, the expression of markers of inflammation (IL1β and TNFα) in the colon was not significantly affected after 8 days of HFS diet or metformin treatment (Fig. 4).

![Figure 2](https://example.com/figure2.png)

**Figure 2.** Effects of HFS diet and metformin treatment on apical glucose transporter gene expression in the different regions of the intestine. GLUT5 and SGLT1 mRNA levels were determined by RT-qPCR in (A) the duodenum, (B) jejunum, (C) ileum and (D) colon of 15 to 18 mice per group (SD standard diet, HFS high fat high sucrose diet, HFS-MET HFS diet with metformin supplementation). *p < 0.05, **p < 0.01, ***p < 0.001, determined by ANOVA followed by Tukey’s multiple comparison test.
Metformin modified the bile acid pool. Bile acid profiling was performed on the caecum at the end of the treatment periods. As shown in Fig. 5, 8 days of HFS diet significantly increased total bile acid levels. Even though metformin did not modify total bile acid levels compared to the HFS group, the treatment tended to increase primary over secondary bile acid ratio and to decrease the hydrophobicity index (Fig. 5).

More specifically, bile acid analysis revealed an increase in cholic acid (CA) levels and a reduction in its main secondary metabolite deoxycholic acid (DCA) upon metformin treatment, whereas the amount of 7-sulfocholic acid was not affected (HFS-MET vs HFS) (Fig. 5). The murine bile acids, beta-muricholic acid (β-MCA) and omega-muricholic acid (ω-MCA) as well as chenodeoxycholic acid (CDCA) were increased by HFS diet, but were not significantly affected by metformin compared to HFS (Fig. 5). Interestingly, the secondary metabolites of CDCA were significantly affected by metformin. We observed a significant increase in ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA) while lithocholic acid (LCA) levels were decreased by the treatment (Fig. 5). Of note, the relative abundance of conjugated bile acids (tauro-, or sulfo-conjugated) was not significantly affected by metformin (data not shown).

Metformin modified the luminal microbiota composition in all the regions of the intestine. The number of operational taxonomic units (OTUs) measured in the luminal effluents in the duodenum, the jejunum and the ileum, was similar between groups, with a trend for a lower number of OTUs in the HFS diet group (p = 0.049 vs SD group), not restored by metformin treatment (Sup. Fig. S1). Despite the fact that the bacterial richness appeared globally not modified after 8 days of HFS diet or metformin treatment, we observed a significant impact of metformin at the phylum level in the different regions of the intestinal tract (Fig. 6). While animals fed the HFS diet displayed a slight increase in the proportion of Firmicutes in all segments, especially the duodenum, metformin treatment induced a spectacular increase in the abundance of Verrucomicrobia all along the intestinal tract (Fig. 6). Analysis performed at the genus level revealed that 60% of the sequenced bacteria belonging to this phylum corresponded to Akkermansia muciniphila, as shown in Fig. 7. Furthermore, additional analyses indicated that HFS diet and metformin treatment were associated with important modifications at the family and genus levels (Fig. 8, Sup. Fig. S2). We observed increased abundance of Clostridium (belonging to the Clostridiaceae family) in all the region of small intestine upon HFS feeding, which was significantly prevented by metformin (Sup. Fig. S2). This effect of metformin treatment on Clostridium was also found in the colon, despite lower abundance of these bacteria in this region (Sup. Fig. S2). Bacteria belonging to the Lachnospiraceae family showed similar trend as Clostridium, especially the genus Dorea, which was increased by HFS diet and restored by metformin in all intestinal segments (Sup. Fig S2). Furthermore, in the lumen of the 3 sections of the small intestine, bacteria belonging to the Peptostreptococcaceae family also showed similar trend to Clostridium, with metformin reducing their abundance (Sup. Fig. S3).
In contrast, metformin treatment tended to increase *Adlercreutzia* abundance in the jejunum (Sup. Fig. S3). We also observed a positive effect of metformin on *Propionibacterium* (from the Actinobacteria phylum) in the duodenum (Sup. Fig. S3). Finally, there was a marked reduction of the Muribaculaceae family (S24-7) in response to HFS diet in the colon and metformin tended to further decrease the abundance of these bacteria (Sup. Fig. S3).

**Discussion**

The mechanism of action of the antidiabetic drug metformin is still a matter of discussions although it is now widely accepted that the gut plays an important role in the management of type 2 diabetes. Despite major advances, there are still uncertainties regarding the effects of metformin in the intestinal tract. In the present study, we aimed at gaining more insights into the mechanisms that occur in the different regions of the intestine in response to 8 days of metformin treatment in a mouse model of high-fat high-sucrose (HFS) diet. Adult male mice fed the HFS diet for 8 days displayed metabolic alterations, as evidenced by mild fasting hyperglycemia and reduced glucose tolerance. Metformin treatment was able to protect against these defects at the whole-body level.

**Effects of metformin on intestinal gene expression.** Dissecting the molecular changes in the different regions of the gut, we found that metformin counteracted HFS diet-induced overexpression of a network of genes involved in the transport of glucose and fatty acids in the small intestine.

The effect of metformin on intestinal glucose transporters is not clear in the literature, although the general consensus is to consider that glucose transport from the intestinal lumen to the circulation is inhibited by metformin, together with an increased uptake and metabolism of glucose by enterocytes. Mice fed the HFS diet were characterized by increased SGLT1 and GLUT5 mRNA levels in the duodenum, and we observed that metformin...
abolished these inductions, and also reduced GLUT5 expression in the ileum and the colon. These data pointed therefore towards a marked inhibition of sugar transporter expression, especially fructose transporter, after 8 days of metformin treatment, in agreement with a recent report showing reduced intestinal glucose absorption in mice in response to metformin17.

The impact of metformin on intestinal lipid transport is less documented. We observed a marked regulation of the expression of genes related to fatty acid transporters (CD36, FATP4, FABP2) and chylomicron synthesis (MTTP) in both ileum and jejunum, the preferential regions of lipid absorption. Metformin counteracted the overexpression induced by HFS diet or downregulated these genes. Inhibition of MTTP expression by metformin, associated with reduced chylomicron production, has been already observed in the Psammomys obesus sand rat model18. These data supported therefore an inhibition by metformin of HFS diet-induced lipid absorption, which may contribute, together with the reduction of sugar transporter expression and absorption17, to the improvement of metabolic homeostasis in treated animals.

Metformin treatment for 8 days also down-regulated the expression of genes coding for GIP and CCK in the duodenum, and for FGF15 in the ileum when compared to the HFS diet group. Fibroblast growth factor 15 (rodent ortholog of the human FGF19) has recently emerged as an important endocrine hormone involved in bile acids, lipid and glucose metabolism19. In agreement with our gene expression data, metformin was found to reduced serum FGF15 levels in a model of diabetic rats20, and reduced FGF19 levels was recently reported after 3 days of treatment in T2DM patients21. GLP-1 is regarded as one of the main mediators of metformin beneficial action on glucose homeostasis and many studies have reported increased glucagon gene expression in intestinal L-cells, as well as higher circulating levels of GLP-1 upon metformin treatment15,22. We did not observe here major modifications of glucagon gene expression in the different regions of the gut, suggesting that the regulation of GLP-1 expression is potentially not a short-term or a primary event in the mechanism of action of metformin in the HFS fed mouse model.

Figure 5. Metformin treatment impacts bile acid pool in the caecum of the mice. Bile acid molecular species concentrations were measured by HPLC coupled to tandem mass spectrometry (HPLC–MS/MS) in caecum of 6 mice per group (SD standard diet, HFS high fat high sucrose diet, HFS-MET HFS diet with metformin supplementation). *p < 0.05, **p < 0.01, ***p < 0.001, determined by ANOVA followed by Tukey's multiple comparison test.
Effects of metformin on microbiota. We evaluated the impact of metformin treatment on the luminal microbiota of each segment of the intestinal tract. The most striking and novel result was a strong induction by metformin of *Akkermansia muciniphila* abundance in all the sections of the gut. The effect of metformin on *A. muciniphila* has been already documented in faeces and stools both in rodent and in human studies. The novelty here was to show that this effect of metformin takes place in all the sections of the gut, including the upper small intestine. *A. muciniphila* classically uses mucins as energy source and leads to the degradation and renewal of the mucus layer, thus maintaining the intestinal barrier function. However, we did not find modification of MUC2 expression in the different segments of the gut (Sup. Fig. S4), although this marker has been previously associated with mucus layer thickness in mice treated by metformin for 10 weeks. This may suggest that other mechanisms could link *A. muciniphila* and metformin action. Interestingly, the beneficial metabolic effect of *A. muciniphila*, has been very recently associated with the production in the gut of mono-palmitoyl-glycerol species, members of the endocannabinoid family. The regulation of these metabolites in the presence of metformin remains to be investigated.

In addition to *A. muciniphila*, we found that metformin reversed the induction by HFS diet of bacteria from the Lachnospiraceae family, including *Dorea*, and from the Clostridiaceae family, especially the genus *Clostridium*, in almost all the sections of the intestine, as well as from the Peptostreptococcaceae family in the small intestine. Reduction in Lachnospiraceae abundance in response to metformin has been already observed in rodent studies. Similarly, several members of the *Clostridium* genus have been found down-regulated in metformin-treated T2DM patients. Members of these families are generally associated with compromised health conditions, like the Lachnospiraceae that are increased in different diseases, including obesity and diabetes. Our data may suggest a contribution of members of these families in HFS diet-induced metabolic alterations and in the beneficial effects of metformin.

Figure 6. Metformin modifies luminal microbiota composition in the different region of the intestine. Microbiota composition was determined by 16S rRNA sequencing in luminal samples form the duodenum, jejunum, ileum and colon of animals of the 3 groups (SD standard diet, HFS high fat high sucrose diet, HFS-MET HFS diet with metformin supplementation). The figure represents the relative abundance of the main bacterial phyla measured in the luminal samples of individual mice.
Metformin treatment seemed also associated with an increase in the abundance of *Adlercreutzia* in the jejunum, with a tendency in the other parts of small intestine, and of *Propionibacterium* in the duodenum. Increased abundance of *Adlercreutzia* has been previously observed in some T2DM patients treated with metformin\(^2\). Interestingly, species of *Adlercreutzia* have been shown to metabolize isoflavonoids to equol that possesses strong antioxidant properties and can favourably affect various metabolic functions\(^3\). Regarding the *Propionibacterium*, several members possess beneficial properties, especially the ability to produce propionate and vitamin B12\(^4\). Increased fecal propionate concentration have been evidenced in T2DM patients treated with metformin\(^1\).

Beside *A. muciniphila*, additional specific bacteria were recently proposed as potential mediator of metformin action, but were not found in the present study, such as *Lactobacillus* members, that are increased after 1 day of metformin treatment in rat duodenum\(^3\), and *Bacteroides fragilis* which is decreased after 3 days of metformin treatment in rat jejunum.\(^3\)

**Figure 7.** Metformin increases *Akkermansia Muciniphila* abundance in the intestinal lumen all along the gut. Microbiota composition was determined by 16S rRNA sequencing in luminal samples from the duodenum, the jejunum, the ileum and the colon in the different groups (SD standard diet, HFS high fat high sucrose diet, HFS-MET HFS diet with metformin supplementation). The figure represents the relative abundance of *Akkermansia Muciniphila* species. **p < 0.01, ***p < 0.001, determined by ANOVA followed by Tukey’s multiple comparison test.
in the stools of T2DM patients and that may regulate FXR signalling through the production of the bile acid GUDCA.

**Effects of metformin on bile acid pool.** The involvement of bile acids in the mechanism of action of metformin has recently emerged. We found here that metformin did not significantly modify total bile acid levels in the caecum of the HFS diet fed mice, but altered their composition. The most striking effect of metformin was a marked decrease in the levels of the secondary bile acids DCA and LCA whereas UDCA and TUDCA were increased. DCA and LCA can be produced by gut bacterial 7α-dehydroxylation (7αDeOH) of the primary bile acids CA and CDCA. The predominant intestinal species exhibiting 7αDeOH activity belong to the genus *Clostridium*. The fact that metformin significantly decreased their abundance in all the sections of the gut, may potentially support the observed reduction in DCA and LCA levels.

Ursodeoxycholic acid (UDCA) and its taurine conjugated TUDCA are of clinical interest due to their multiple beneficial effects on human health. CDCA can be converted to UDCA in the colon through epimerization by microbial 7α- and 7β-hydroxysteroid dehydrogenases. The bacteria bearing 7αβ-hydroxysteroid dehydrogenase activities are less characterized, but members of the genera *Clostridium* possess these activities. UDCA is then transported from the intestine to the liver through the enterohepatic circulation where it is conjugated with taurine or glycine to produce TUDCA or GUDCA, which are transported back into the gut. We found increased levels of UDCA and TUDCA in the caecum of metformin treated mice, while GUDCA was not detectable (in agreement with the fact that there are very low levels of glycoconjugated bile acids in rodent). Our data in mice agreed therefore with a recent study showing that TUDCA and GUDCA are the most induced bile acids in the stool of T2DM patients treated for 3 days with metformin. These authors also showed that TUDCA, GUDCA and UDCA are inhibitors of the nuclear receptor FXR. Interestingly, DCA and LCA, which were increased in the present study, are also potential inhibitors of FXR. Another study demonstrated that metformin could also directly inhibit FXR activity via AMPK activation. Supporting an inhibition of FXR activity in metformin treated mice, we found a significant reduction in the expression level of FGF15, a major target gene of FXR.

**Figure 8.** Metformin induces changes of the luminal microbiota composition in the different region of the intestine. Microbiota composition was determined by 16S rRNA sequencing in luminal samples form the duodenum, jejunum, ileum and colon of animals of the 3 groups (SD standard diet, HFS high fat high sucrose diet, HFS-MET HFS diet with metformin supplementation). The figure represents the relative abundance of the main measurable bacterial families and genera in the luminal samples of individual mice.
the ileum. Therefore, the contribution of FXR signalling in the action of metformin, directly or via bile acid modifications in the gut, is certainly an important mechanism to take into consideration.

Altogether the presented data demonstrate that metformin administrated during 8 days is able to counteract important perturbations induced by HFS diet in the different regions of the intestinal tract in mice, including altered expression of key genes of nutrient absorption and increased abundance of some gut bacteria, which have been associated with metabolic disturbances (F-Lachnospiraceae, F-Petostreptococcaceae, g. Clostridium). In addition, metformin promotes a strong increase in the abundance of A. muciniphila along all the gut, and beneficial modification of secondary bile acid profile in the caecum, with reduction in DCA and LCA levels and increased levels of UDCA and TUDCA, potentially leading to FRX inhibition. It will be now important to determine how these different events are interconnected and triggered by metformin. A limitation of the present work is the fact that metformin administration was initiated together with the HFS diet, therefore interfering with the adaptation of the mice to the diet. The results might thus by different in a therapeutic approach with metformin treatment provided in animals with already established metabolic alterations. Another limitation is the fact that the study did not include a control group to investigate the effects of metformin in mice fed the chow diet. Although such studies should be performed in the future, the present work clearly emphasises the role of all the regions of the intestine in the beneficial action of the antidiabetic drug metformin in prediabetic mice.

Methods
Animals, diet and metformin treatment. Twelve-week-old C57BL/6J/Ola/Hsd male mice (ENVIGO, Gannat, France) were maintained in a temperature-controlled (22 ± 2 °C) facility room with a 12 h light/dark cycle. Animals were allocated to 3 experimental groups (n = 5/6 animals per group) after one week of adaptation. The protocol was independently repeated 4 times. The control group (SD) was fed ad libitum with classical chow diet (R16, GENOBIOS, Laval, France), the HFS and HFS-MET groups were fed with a high-fat high-sugar diet (260HF, SAFE, Augy, France, composition shown in the Supplementary Table S1) for a period of 8 days while treated daily by intragastric gavage of metformin (300 mg/day/kg body weight) (HFS-MET) or water as control (HFS). Housing and experimentations were carried out in compliance with the ARRIVE guidelines and according to the French and European guidelines of laboratory animal care (European Communities Council Directive 2010/63/EU) and registered under the reference CECCAP LS-2017-002.

Body weight was monitored at day 0 and day 8. For glucose tolerance test (ipGTT), mice were fasted for 6 h and then received an intraperitoneal injection of glucose (2 g/kg body weight). Blood glucose was monitored at different time points during 90 min at the tip of the tail, using a glucometer (Accu-Check, ROCHE).

Intestinal tissue sampling. Animals were killed by cervical dislocation after 6 h of fasting and 5 h after the last gavage with metformin. Different parts of the intestinal tract (duodenum, jejunum, ileum and the colon from medium part to anus) were sampled. The caecum was also removed and the intestinal segments were cleaned by flushing with ice-cold PBS and dipped in liquid nitrogen.

Gene expression analyses in intestinal segments. Total RNA was extracted with TRI Reagent Solution (SIGMA). Target mRNA levels were measured by reverse transcription followed by real-time PCR using a Rotor-Gene (QIAGEN). A standard curve was systematically generated with different amounts of purified target cDNA, and each assay was performed in duplicate and normalized using TATA-binding protein mRNA level, as previously reported47. The list of the target genes with the PCR primers used for the qPCR assays is in Supplementary Table S2.

Bile acid profiling in caecum. Bile acid molecular species concentrations were measured by HPLC coupled to tandem mass spectrometry (HPLC–MS/MS) as previously described38. Results were expressed in nmol/g of dried caecum.

Microbiota analysis. Microbiota composition in the luminal content of the different intestinal sections was determined by 16S rRNA sequencing in 5 animals per group. At sacrifice, the different parts of the intestinal tract (duodenum, jejunum, ileum, colon) were carefully flushed 3 times with 5 ml of ice-cold PBS. The eluents were combined and centrifuged at 1800 rpm during 20 min at 4 °C. The supernatants were discarded and the pellets suspended in 300 μl of RNA later (SIGMA ALDRICH) and stored at −80 °C until use. Total DNA was extracted with the QIAamp PowerFecal DNA Kit (QIAGEN). Library preparation and sequencing were outsourced to the Biomnigene company (https://www.biomnigene.fr/en/). A region of approximately 426 bp encompassing the V3 and V4 hypervariable regions of the 16s tDNA gene was targeted for sequencing. For the preparation of the libraries, “Illumina TrueSeqDNA Sample Preparation v2” was used. Sequencing was performed on Illumina MiSeq2000. Quality check was performed by FASTQC and sequences were then trimmed, denoised and chimeras filtered using the DADA2 plugin. Then, OTU annotation, taxonomy classification and analyses were performed using the Quantitative Insights Into Microbial Ecology (QIIME2 version 2019.4) platform39, using the fit-classifier-naive-bayes module with the default parameters and the Greengenes database (gg_13_8_otus.tar.gz classifier for 16S rRNA). On the 60 luminal samples prepared (4 intestinal sections of 5 animals per group), 10 samples were removed from the analysis because of too low number of reads after sequencing (<80,000) and/or aberrant results showing the presence of only one bacteria family, not found in any other samples, reflecting thus possible amplification artifacts40. On the remaining 50 samples, a total of 6,504,328 valid reads were obtained.
**Statistical analyses.** Data are presented as mean ± SEM. For the measured parameters, ordinary one-way ANOVA followed by Tukey’s multiple comparison test was performed using GRAPHPAD PRISM version 8.0. p < 0.05 was considered statistically significant.

**Data availability**
The datasets generated and analyzed during this study are available from the corresponding author on reasonable request.

Received: 19 March 2021; Accepted: 21 July 2021
Published online: 17 August 2021

**References**
1. Foretz, M., Guigas, B. & Viollet, B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. *Nat. Rev. Endocrinol.* **15**, 569–589 (2019).
2. Vial, G., Detaille, D. & Guigas, B. Role of mitochondria in the mechanism(s) of action of metformin. *Front. Endocrinol.* **10**, 294 (2019).
3. Hundal, R. S. et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. *Diabetes* **49**, 2063–2069 (2000).
4. Wilcock, C. & Bailey, C. J. Accumulation of metformin by tissues of the normal and diabetic mouse. * Xenobiot. Fate Foreign Compd. Biol. Syst.* **24**, 49–57 (1994).
5. Sum, C. F. et al. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. *Diabet. Med. J. Br. Diabet. Assoc.* **9**, 61–65 (1992).
6. Buse, J. B. et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: Results from short-term pharmacokinetic and 12-week dose-ranging studies. *Diabetes Care* **39**, 198–205 (2016).
7. Ikeda, T., Iwata, K. & Murakami, H. Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine. *Biochem. Pharmacol.* **59**, 887–890 (2000).
8. Gontier, E. et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. *Eur. J. Nucl. Med. Mol. Imaging* **35**, 95–99 (2008).
9. Bahne, E. et al. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. *JCI Insight.* [https://doi.org/10.1172/jci.insight.93936] (2018).
10. Shin, N.-R. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut* **63**, 727–735 (2014).
11. Sansom, D. J. et al. Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids. *Diabetes Obes. Metab.* **22**, 141–148 (2020).
12. Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature* **528**, 262–266 (2015).
13. Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naïve type 2 diabetes, contributing to the therapeudic effects of the drug. *Nat. Med.* **23**, 850–858 (2017).
14. Lee, H. & Ko, G. Effect of metformin on metabolic improvement and gut microbiota. *Appl. Environ. Microbiol.* **80**, 5935–5943 (2014).
15. Zhang, X. et al. Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats. *Sci. Rep.* **5**, 14405 (2015).
16. Adeshirliarjaney, A., Zou, J., Tran, H. Q., Chassaing, B. & Gewirtz, A. T. Amelioration of metabolic syndrome by metformin association with reduced indices of low-grade inflammation independently of the gut microbiota. *Am. J. Physiol. Endocrinol. Metab.* **317**, E1121–E1130 (2019).
17. Horakova, O. et al. Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. *Sci. Rep.* **9**, 6156 (2019).
18. Harmel, E. et al. AMPK in the small intestine in normal and pathophysiological conditions. *Endocrinology* **155**, 873–888 (2014).
19. Degirolamo, C., Sabba, C. & Mochetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGFR1, FGFR2 and FGFR3. *Nat. Rev. Drug Discov.* **15**, 51–69 (2016).
20. Wang, Y. et al. The effects of metformin on fibroblast growth factor 19, 21 and fibroblast growth factor receptor 1 in high-fat diet and streptozotocin induced diabetic rats. *Endocr. J.* **64**, 543–552 (2017).
21. Sun, L. et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. *Nat. Med.* **24**, 1919–1929 (2018).
22. Brenden, A. et al. Single-dose metformin enhances bile acid-induced glucagon-like peptide-1 secretion in patients with type 2 diabetes. *J. Clin. Endocrinol. Metab.* **102**, 4153–4162 (2017).
23. Ouyang, J. et al. The bacterium *Akkermansia muciniphila*: A sentinel for gut permeability and its relevance to HIV-related inflammation. *Front. Immunol.* **11**, 645 (2020).
24. Depommer, C. et al. Beneficial effects of akkermansia muciniphila are not associated with major changes in the circulating endocannabinoidome but linked to higher mono-palmitoyl-glycerol levels as new PPARα agonists. *Cells* **10**, 185 (2021).
25. Ma, W. et al. Metformin alters gut microbiota of healthy mice: Implication for its potential role in gut microbiota homeostasis. *Front. Microbiol.* **9**, 1336 (2018).
26. Vacca, M. et al. The controversial role of human gut lachnospiraceae. *Microorganisms* **8**, 573 (2020).
27. Kameyama, K. & Itoh, K. Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice. *Microbes Environ.* **29**, 427–430 (2014).
28. Napolitano, A. et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. *PLoS ONE* **9**, e100778 (2014).
29. Setchell, K. D. R. & Clerici, C. Equol: Pharmacokinetics and biological actions. *J. Nutr.* **140**, 1363S–S1368 (2010).
30. Piwowarek, K., Lipińska, E., Hać-Szymańczuk, E., Kieliszek, M. & Ścibisz, I. Propionibacterium spp.-source of propionic acid, vitamin B12, and other metabolites important for the industry. *Appl. Microbiol. Biotechnol.* **102**, 515–538 (2018).
31. Bauer, P. V. et al. Metformin alters upper small intestinal microbiota that impact a glucose-SGLT1-sensing glucoregulatory pathway. *Cell Metab.* **27**, 101–117 (2018).
32. Doerner, K. C., Takamine, F., LaVoie, C. P., Mallonee, D. H. & Hylemon, P. B. Assessment of fecal bacteria with bile acid 7 alpha-dehydroxylating activity for the presence of bai-like genes. *Appl. Environ. Microbiol.* **63**, 1185–1188 (1997).
33. Funabashi, M. et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome. *Nature* **582**, 566–570 (2020).
34. Lepereq, P. et al. Epimerization of chenodeoxycholic acid to ursodeoxycholic acid by Clostridium baratii isolated from human feces. *FEBS Microbiol. Lett.* **235**, 65–72 (2004).
35. Yu, J. et al. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. *J. Biol. Chem.* **277**, 31441–31447 (2002).
36. Lien, F. et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. *J. Clin. Investig.* **124**, 1037–1051 (2014).
37. Naville, D. et al. Chronic exposure to a pollutant mixture at low doses led to tissue-specific metabolic alterations in male mice fed standard and high-fat high-sucrose diet. *Chemosphere* **220**, 1187–1199 (2019).
38. Humbert, L. et al. Bile acid profiling in human biological samples: Comparison of extraction procedures and application to normal and cholestatic patients. *J. Chromatogr. B Anal. Technol. Biomed. Life. Sci.* **899**, 135–145 (2012).
39. Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat. Biotechnol.* **37**, 852–857 (2019).
40. Wooley, J. C. & Ye, Y. Metagenomics: Facts and artifacts, and computational challenges. *J. Comput. Sci. Technol.* **25**, 71–81 (2009).

**Acknowledgements**

This work was funded by grants from the “Fondation Francophone pour la Recherche sur le Diabète” (FFRD 2018) (PROBIO 2018), from Région Auvergne-Rhône-Alpes (“Pack Ambition Recherche » Probiodiab 2017) and from INSERM (French transversal program on microbiota).

**Author contributions**

C.G., K.M., J.R. and H.V. conceived and designed the study. A.B., C.G., C.D., B.B., K.M. and M.G. conducted the mouse experiments, the metabolic phenotyping and the genomic analyses. C.D. and E.M. performed the microbiota study. B.B. and D.R. performed and interpreted the bile acid analyses. B.B., C.D., M.G. and H.V. analyzed and interpreted the data. H.V. wrote the manuscript with corrections and approval of all the co-authors.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-95117-0.

**Correspondence** and requests for materials should be addressed to H.V.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021